Circulating amino acid signature features urea cycle alterations associated with coronary artery disease.
Amino acids
Coronary artery disease
Metabolic profiling
Metabolic signature
Urea cycle
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 10 2024
28 10 2024
Historique:
received:
01
04
2024
accepted:
17
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Coronary artery disease (CAD) remains a leading cause of death worldwide and imposes a substantial socioeconomic burden on healthcare. Improving risk stratification in clinical practice could help to combat this burden. As amino acids are biologically active metabolites whose involvement in CAD remains largely unknown, this study investigated associations between circulating amino acid levels and CAD phenotypes. A high-coverage quantitative liquid chromatography-mass spectrometry approach was applied to acquire the serum amino acids profile of age- and sex-coarsened-matched patients with CAD (n = 46, 66.9 years, 74.7% male) and healthy individuals (n = 120, 67.4 years, 74.7% male) from the COmPLETE study. Multiple linear regressions were performed to investigate associations between amino acid levels and (a) the health status (CAD vs. healthy), (b) the number of affected coronary arteries, or (c) the left ventricular ejection fraction. Regressions were adjusted for age, sex, daily physical activity, sampling, and fasting time. Urea cycle amino acids (ornithine, citrulline, homocitrulline, aspartate, and arginine) were significantly and negatively associated with CAD, the number of affected coronary arteries, and the left ventricular ejection fraction. Lysine, histidine, and the glutamine/glutamate ratio were also significantly and negatively associated with the CAD phenotypes. Overall, patients with CAD displayed lower levels of urea cycle amino acids, highlighting a potential role for urea cycle amino acid profiling in cardiovascular risk stratification.Trial registrationThe study was registered on https://www.clinicaltrials.gov (NCT03986892) on June 5, 2019.
Identifiants
pubmed: 39468229
doi: 10.1038/s41598-024-76835-7
pii: 10.1038/s41598-024-76835-7
doi:
Substances chimiques
Amino Acids
0
Urea
8W8T17847W
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT03986892']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25848Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 316030_183377
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 182815
Informations de copyright
© 2024. The Author(s).
Références
Murray, C. J. L. et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2 (2020).
doi: 10.1016/S0140-6736(20)30752-2
Benziger, C. P., Roth, G. A. & Moran, A. E. The global burden of disease study and the preventable burden of NCD. Glob. Heart 11, 393–397. https://doi.org/10.1016/j.gheart.2016.10.024 (2016).
doi: 10.1016/j.gheart.2016.10.024
pubmed: 27938824
Mach, F. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 41, 111–188. https://doi.org/10.1093/eurheartj/ehz455 (2019).
doi: 10.1093/eurheartj/ehz455
Wu, Z. et al. Circulating cardiac biomarkers improve risk stratification for incident cardiovascular disease in community dwelling populations. eBioMedicine. https://doi.org/10.1016/j.ebiom.2022.104170 (2022).
Shah, S. H., Kraus, W. E. & Newgard, C. B. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 126, 1110–1120. https://doi.org/10.1161/circulationaha.111.060368 (2012).
doi: 10.1161/circulationaha.111.060368
pubmed: 22927473
pmcid: 4374548
Dai, Z., Zheng, W. & Locasale, J. W. Amino acid variability, tradeoffs and optimality in human diet. Nat. Commun. 13, 6683. https://doi.org/10.1038/s41467-022-34486-0 (2022).
doi: 10.1038/s41467-022-34486-0
pubmed: 36335142
pmcid: 9637229
Teav, T. et al. Merged targeted quantification and untargeted profiling for comprehensive assessment of acylcarnitine and amino acid metabolism. Anal. Chem. 91, 11757–11769. https://doi.org/10.1021/acs.analchem.9b02373 (2019).
doi: 10.1021/acs.analchem.9b02373
pubmed: 31407894
Green, C. R. et al. Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis. Nat. Chem. Biol. 12, 15–21. https://doi.org/10.1038/nchembio.1961 (2016).
doi: 10.1038/nchembio.1961
pubmed: 26571352
Würtz, P. et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 131, 774–785. https://doi.org/10.1161/circulationaha.114.013116 (2015).
doi: 10.1161/circulationaha.114.013116
pubmed: 25573147
pmcid: 4351161
McGarrah, R. W. & White, P. J. Branched-chain amino acids in cardiovascular disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00760-3 (2022).
doi: 10.1038/s41569-022-00760-3
pubmed: 36064969
pmcid: 10284296
Nitz, K., Lacy, M. & Atzler, D. Amino acids and their metabolism in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 39, 319–330. https://doi.org/10.1161/ATVBAHA.118.311572 (2019).
Wagner, J. et al. Functional aging in health and heart failure: The COmPLETE Study. BMC Cardiovasc. Disord. 19, 180. https://doi.org/10.1186/s12872-019-1164-6 (2019).
doi: 10.1186/s12872-019-1164-6
pubmed: 31362698
pmcid: 6664502
Knuuti, J. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur. Heart J. 41, 407–477. https://doi.org/10.1093/eurheartj/ehz425 (2019).
doi: 10.1093/eurheartj/ehz425
Gander, J. et al. Metabolic impairment in coronary artery disease: Elevated serum acylcarnitines under the spotlights. Front. Cardiovasc. Med. 8. https://doi.org/10.3389/fcvm.2021.792350 (2021).
Lancellotti, P. & Cosyns, B. The EACVI Echo Handbook (Oxford University Press, 2015).
Gudmundsson, P., Rydberg, E., Winter, R. & Willenheimer, R. Visually estimated left ventricular ejection fraction by echocardiography is closely correlated with formal quantitative methods. Int. J. Cardiol. 101, 209–212. https://doi.org/10.1016/j.ijcard.2004.03.027 (2005).
Esliger, D. W. et al. Validation of the GENEA accelerometer. Med. Sci. Sports Exerc. 43, 1085–1093. https://doi.org/10.1249/MSS.0b013e31820513be (2011).
doi: 10.1249/MSS.0b013e31820513be
pubmed: 21088628
Ho, D., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric preprocessing for parametric causal inference. J. Stat. Softw. 42, 1–28. https://doi.org/10.18637/jss.v042.i08 (2011).
Iacus, S. M., King, G. & Porro, G. Causal inference without balance checking: Coarsened exact matching. Polit. Anal. 20, 1–24. https://doi.org/10.1093/pan/mpr013 (2012).
doi: 10.1093/pan/mpr013
Özcan, C. et al. Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: A Danish nationwide register-based cohort study. Eur. Heart J. Cardiovasc. Pharmacother. 4, 25–35. https://doi.org/10.1093/ehjcvp/pvx009 (2018).
doi: 10.1093/ehjcvp/pvx009
pubmed: 28444162
Sponder, M., Fritzer-Szekeres, M., Marculescu, R., Litschauer, B. & Strametz-Juranek, J. A new coronary artery disease grading system correlates with numerous routine parameters that were associated with atherosclerosis: A grading system for coronary artery disease severity. Vasc. Health Risk Manag. 10, 641–647. https://doi.org/10.2147/vhrm.S68919 (2014).
doi: 10.2147/vhrm.S68919
pubmed: 25404859
pmcid: 4230172
Gensini, G. G. A more meaningful scoring system for determining the severity of coronary heart disease. Am. J. Cardiol. 51, 606. https://doi.org/10.1016/s0002-9149(83)80105-2 (1983).
doi: 10.1016/s0002-9149(83)80105-2
pubmed: 6823874
Mortensen, M. B. et al. CAD severity on cardiac CTA identifies patients with most benefit of treating LDL-cholesterol to ACC/AHA and ESC/EAS targets. JACC Cardiovasc. Imaging 13, 1961–1972. https://doi.org/10.1016/j.jcmg.2020.03.017 (2020).
doi: 10.1016/j.jcmg.2020.03.017
pubmed: 32563656
Liu, Y. et al. Association of ejection fraction with mortality and cardiovascular events in patients with coronary artery disease. ESC Heart Fail. 9, 3461–3468. https://doi.org/10.1002/ehf2.14063 (2022).
doi: 10.1002/ehf2.14063
pubmed: 35866195
pmcid: 9715855
Maragiannis, D. et al. Association of left ventricular diastolic dysfunction with subclinical coronary atherosclerotic disease burden using coronary artery calcium scoring. J. Atheroscler. Thromb. 22, 1278–1286. https://doi.org/10.5551/jat.29454 (2015).
doi: 10.5551/jat.29454
pubmed: 26269148
Textor, J., van der Zander, B., Gilthorpe, M. S., Liskiewicz, M. & Ellison, G. T. Robust causal inference using directed acyclic graphs: The R package “dagitty”. Int. J. Epidemiol. 45, 1887–1894. https://doi.org/10.1093/ije/dyw341 (2016).
doi: 10.1093/ije/dyw341
pubmed: 28089956
McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726. https://doi.org/10.1093/eurheartj/ehab368 (2021).
doi: 10.1093/eurheartj/ehab368
pubmed: 34447992
Stevens, P. E. et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117–S314. https://doi.org/10.1016/j.kint.2023.10.018 (2024).
doi: 10.1016/j.kint.2023.10.018
transplantr: Audit and Research Functions for Transplantation v. 0.2.0 (2020).
Liang, K.-Y. & Zeger, S. L. Longitudinal data analysis using generalized linear models. Biometrika 73, 13–22. https://doi.org/10.1093/biomet/73.1.13 (1986).
doi: 10.1093/biomet/73.1.13
Abadie, A. & Spiess, J. Robust post-matching inference. J. Am. Stat. Assoc. 117, 983–995. https://doi.org/10.1080/01621459.2020.1840383 (2022).
doi: 10.1080/01621459.2020.1840383
Schielzeth, H. Simple means to improve the interpretability of regression coefficients. Methods Ecol. Evol. 1, 103–113. https://doi.org/10.1111/j.2041-210X.2010.00012.x (2010).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57, 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x (1995).
R Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, 2020). https://www.R-project.org/
Williams, B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J. 39, 3021–3104. https://doi.org/10.1093/eurheartj/ehy339 (2018).
doi: 10.1093/eurheartj/ehy339
pubmed: 30165516
Matsumoto, S. et al. Urea cycle disorders—update. J. Hum. Genet. 64, 833–847. https://doi.org/10.1038/s10038-019-0614-4 (2019).
doi: 10.1038/s10038-019-0614-4
pubmed: 31110235
Farah, C., Michel, L. Y. M. & Balligand, J.-L. Nitric oxide signalling in cardiovascular health and disease. Nat. Rev. Cardiol. 15, 292–316. https://doi.org/10.1038/nrcardio.2017.224 (2018).
doi: 10.1038/nrcardio.2017.224
pubmed: 29388567
Stuehr, D. J. Enzymes of the L-arginine to nitric oxide pathway. J. Nutr. 134, 2748S–2751S. https://doi.org/10.1093/jn/134.10.2748S (discussion 2765S–2767S) (2004).
Wilson, A. M., Harada, R., Nair, N., Balasubramanian, N. & Cooke, J. P. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 116, 188–195. https://doi.org/10.1161/circulationaha.106.683656 (2007).
doi: 10.1161/circulationaha.106.683656
pubmed: 17592080
An, P. et al. Micronutrient supplementation to reduce cardiovascular risk. J. Am. Coll. Cardiol. 80, 2269–2285. https://doi.org/10.1016/j.jacc.2022.09.048 (2022).
Popolo, A., Adesso, S., Pinto, A., Autore, G. & Marzocco, S. l-Arginine and its metabolites in kidney and cardiovascular disease. Amino Acids 46, 2271–2286. https://doi.org/10.1007/s00726-014-1825-9 (2014).
doi: 10.1007/s00726-014-1825-9
pubmed: 25161088
Tsikas, D., Bollenbach, A., Hanff, E. & Kayacelebi, A. A. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): The ADMA, SDMA and hArg paradoxes. Cardiovasc. Diabetol. 17, 1. https://doi.org/10.1186/s12933-017-0656-x (2018).
doi: 10.1186/s12933-017-0656-x
pubmed: 29301528
pmcid: 5753492
Wang, Z. et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13, 1176–1184. https://doi.org/10.1038/nm1637 (2007).
doi: 10.1038/nm1637
pubmed: 17828273
Jaisson, S. et al. Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease. Clin. Chem. Lab. Med. 53, 103–110. https://doi.org/10.1515/cclm-2014-0642 (2015).
doi: 10.1515/cclm-2014-0642
pubmed: 25153409
Cheng, S. et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 125, 2222–2231. https://doi.org/10.1161/circulationaha.111.067827 (2012).
doi: 10.1161/circulationaha.111.067827
pubmed: 22496159
pmcid: 3376658
Zheng, Y. et al. Metabolites of glutamate metabolism are associated with incident cardiovascular events in the PREDIMED PREvención con DIeta MEDiterránea (PREDIMED) Trial. J. Am. Heart Assoc. 5. https://doi.org/10.1161/jaha.116.003755 (2016).
Palmer, N. D. et al. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. J. Clin. Endocrinol. Metab. 100, E463–E468. https://doi.org/10.1210/jc.2014-2357 (2015).
doi: 10.1210/jc.2014-2357
pubmed: 25423564
Cabrera, O. et al. Glutamate is a positive autocrine signal for glucagon release. Cell Metab. 7, 545–554. https://doi.org/10.1016/j.cmet.2008.03.004 (2008).
doi: 10.1016/j.cmet.2008.03.004
pubmed: 18522835
pmcid: 4396785
Lehn-Stefan, A. et al. Elevated circulating glutamate is associated with subclinical atherosclerosis independently of established risk markers: A cross-sectional study. J. Clin. Endocrinol. Metab. 106, e982–e989. https://doi.org/10.1210/clinem/dgaa898 (2021).
doi: 10.1210/clinem/dgaa898
pubmed: 33277657
Ma, W. et al. Dietary glutamine, glutamate and mortality: Two large prospective studies in US men and women. Int. J. Epidemiol. 47, 311–320. https://doi.org/10.1093/ije/dyx234 (2018).
doi: 10.1093/ije/dyx234
pubmed: 29140419
Durante, W. The emerging role of L-glutamine in cardiovascular health and disease. Nutrients 11. https://doi.org/10.3390/nu11092092 (2019).
Münzel, T. et al. Impact of oxidative stress on the heart and vasculature: Part 2 of a 3-Part series. J. Am. Coll. Cardiol. 70, 212–229. https://doi.org/10.1016/j.jacc.2017.05.035 (2017).
Brosnan, M. E. & Brosnan, J. T. Histidine metabolism and function. J. Nutr. 150, 2570S-2575S. https://doi.org/10.1093/jn/nxaa079 (2020).
doi: 10.1093/jn/nxaa079
pubmed: 33000155
pmcid: 7527268
Thalacker-Mercer, A. E. & Gheller, M. E. Benefits and adverse effects of histidine supplementation. J. Nutr. 150, 2588S-2592S. https://doi.org/10.1093/jn/nxaa229 (2020).
doi: 10.1093/jn/nxaa229
pubmed: 33000165
Hakuno, D., Hamba, Y., Toya, T. & Adachi, T. Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failure. PLoS One 10, e0117325. https://doi.org/10.1371/journal.pone.0117325 (2015).
doi: 10.1371/journal.pone.0117325
pubmed: 25658112
pmcid: 4319965
Anand, S. K. et al. Amino acid metabolism and atherosclerotic cardiovascular disease. Am. J. Pathol. 194, 510–524. https://doi.org/10.1016/j.ajpath.2023.12.006 (2024).
doi: 10.1016/j.ajpath.2023.12.006
pubmed: 38171450
Baumgartner, R., Forteza, M. J. & Ketelhuth, D. F. J. The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis. Cytokine 122, 154148. https://doi.org/10.1016/j.cyto.2017.09.004 (2019).
doi: 10.1016/j.cyto.2017.09.004
pubmed: 28899580
Metghalchi, S. et al. Indoleamine 2,3-dioxygenase fine-tunes immune homeostasis in atherosclerosis and colitis through repression of interleukin-10 production. Cell Metab. 22, 460–471. https://doi.org/10.1016/j.cmet.2015.07.004 (2015).
Pedersen, E. R. et al. Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris. Arterioscler. Thromb. Vasc. Biol. 35, 455–462. https://doi.org/10.1161/atvbaha.114.304674 (2015).
doi: 10.1161/atvbaha.114.304674
pubmed: 25524770
Pawlak, K., Domaniewski, T., Mysliwiec, M. & Pawlak, D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 204, 309–314. https://doi.org/10.1016/j.atherosclerosis.2008.08.014 (2009).
doi: 10.1016/j.atherosclerosis.2008.08.014
pubmed: 18823890
Lee, H. J. et al. 2-Aminoadipic acid (2-AAA) as a potential biomarker for insulin resistance in childhood obesity. Sci. Rep. 9, 13610. https://doi.org/10.1038/s41598-019-49578-z (2019).
doi: 10.1038/s41598-019-49578-z
pubmed: 31541119
pmcid: 6754510
Wang, T. J. et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J. Clin. Investig. 123, 4309–4317. https://doi.org/10.1172/jci64801 (2013).
doi: 10.1172/jci64801
pubmed: 24091325
pmcid: 3784523
Saremi, A. et al. Advanced Glycation end products, oxidation products, and the extent of atherosclerosis during the VA Diabetes Trial and follow-up study. Diabetes Care 40, 591–598. https://doi.org/10.2337/dc16-1875 (2017).
doi: 10.2337/dc16-1875
pubmed: 28148544
pmcid: 5360279
Shi, M. et al. Genetic architecture of plasma alpha-aminoadipic acid reveals a relationship with high-density lipoprotein cholesterol. J. Am. Heart Assoc. 11, e024388. https://doi.org/10.1161/jaha.121.024388 (2022).
doi: 10.1161/jaha.121.024388
pubmed: 35621206
pmcid: 9238724
Desine, S. et al. Association of alpha-aminoadipic acid with cardiometabolic risk factors in healthy and high-risk individuals. Front. Endocrinol. 14. https://doi.org/10.3389/fendo.2023.1122391 (2023).
Wyss, M. & Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol. Rev. 80, 1107–1213. https://doi.org/10.1152/physrev.2000.80.3.1107 (2000).
doi: 10.1152/physrev.2000.80.3.1107
pubmed: 10893433
Levin, A. et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Known knowns and known unknowns. Kidney Int. 105, 684–701. https://doi.org/10.1016/j.kint.2023.10.016 (2024).
doi: 10.1016/j.kint.2023.10.016
pubmed: 38519239
Chen, S. et al. Predictive effect of estimated glomerular filtrate rate by creatinine or cystatin C on mortality in patients with coronary artery disease. Ren. Fail. 46, 2327494. https://doi.org/10.1080/0886022x.2024.2327494 (2024).
doi: 10.1080/0886022x.2024.2327494
pubmed: 38566467
pmcid: 10993740
Gosse, P. & Safar, M. E. Arterial stiffness and plasma creatinine in untreated hypertensive patients. Am. J. Hypertens. 18, 1140–1145. https://doi.org/10.1016/j.amjhyper.2005.04.008 (2005).
doi: 10.1016/j.amjhyper.2005.04.008
pubmed: 16182102
Shah, S. H. et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet. 3, 207–214. https://doi.org/10.1161/CIRCGENETICS.109.852814 (2010).
Bhattacharya, S. et al. Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis 232, 191–196. https://doi.org/10.1016/j.atherosclerosis.2013.10.036 (2014).
doi: 10.1016/j.atherosclerosis.2013.10.036
pubmed: 24401236
Zhenyukh, O. et al. Branched-chain amino acids promote endothelial dysfunction through increased reactive oxygen species generation and inflammation. J. Cell. Mol. Med. 22, 4948–4962. https://doi.org/10.1111/jcmm.13759 (2018).
doi: 10.1111/jcmm.13759
pubmed: 30063118
pmcid: 6156282
Xu, Y. et al. Branched-chain amino acid catabolism promotes thrombosis risk by enhancing tropomodulin-3 propionylation in platelets. Circulation 142, 49–64. https://doi.org/10.1161/circulationaha.119.043581 (2020).
doi: 10.1161/circulationaha.119.043581
pubmed: 32200651
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131. https://doi.org/10.1056/NEJMoa1707914 (2017).
Bröer, S. & Bröer, A. Amino acid homeostasis and signalling in mammalian cells and organisms. Biochem. J. 474, 1935–1963. https://doi.org/10.1042/bcj20160822 (2017).
doi: 10.1042/bcj20160822
pubmed: 28546457
Zheng, Y. et al. Metabolites of glutamate metabolism are associated with incident cardiovascular events in the PREDIMED PREvencion con DIeta MEDiterranea (PREDIMED) Trial. J. Am. Heart Assoc. 5, e003755. https://doi.org/10.1161/JAHA.116.003755 (2016)
Lundberg, J. O., Gladwin, M. T. & Weitzberg, E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat. Rev. Drug Discov. 14, 623–641. https://doi.org/10.1038/nrd4623 (2015).
doi: 10.1038/nrd4623
pubmed: 26265312
Neill, M. A., Aschner, J., Barr, F. & Summar, M. L. Quantitative RT-PCR comparison of the urea and nitric oxide cycle gene transcripts in adult human tissues. Mol. Genet. Metab. 97, 121–127. https://doi.org/10.1016/j.ymgme.2009.02.009 (2009).
Pearson, D. L. et al. Neonatal pulmonary hypertension. N. Engl. J. Med. 344, 1832–1838. https://doi.org/10.1056/nejm200106143442404 (2001).
doi: 10.1056/nejm200106143442404
pubmed: 11407344